IMGN - ImmunoGen, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

ImmunoGen, Inc.

830 Winter Street
Waltham, MA 02451
United States
781-895-0600
http://www.immunogen.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees293

Key Executives

NameTitlePayExercisedYear Born
Mr. Mark J. EnyedyPres, CEO & Director568.98kN/A1964
Mr. David B. JohnstonExec. VP & CFO279.44kN/A1955
Dr. Richard J. GregoryExec. VP & Chief Scientific Officer312.48kN/A1958
Mr. Craig BarrowsExec. VP, Gen. Counsel & Sec.N/AN/A1955
Dr. Anna BerkenblitVP & Chief Medical Officer269.23kN/A1970
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ImmunoGen, Inc., a clinical-stage biotechnology company, focuses on developing antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm, as well as coltuximab ravtansine, a CD19-targeting ADC, which is in Phase II trial for DLBCL. ImmunoGen, Inc. has collaborations with Roche; Bayer HealthCare AG; Sanofi; Biotest AG; Novartis Institutes for BioMedical Research, Inc.; Eli Lilly and Company; Amgen; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Jazz Pharmaceuticals plc; and Debiopharm International SA. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

Corporate Governance

ImmunoGen, Inc.’s ISS Governance QualityScore as of October 1, 2018 is 4. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 5; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.